Abstract
One of the principal roles of the National Institute for Clinical Excellence (NICE) is to appraise selected existing and emerging healthcare technologies and, as a result, produce guidance for the National Health Service (NHS) in England and Wales. A central part of this appraisal is the potential for manufacturers and sponsors to make a data submission. This paper describes the process of development of the second edition of technical guidance to manufacturers and sponsors for submission to NICE. The revision process took place during the period May 2000 and January 2001 and involved a number of key steps - establishment of a guidance steering committee, review of current international guidelines of clinical and cost effectiveness, drafting of the guidance, detailed consultation with stakeholders, revision of the guidance and, finally, publication. The lessons learnt from revision of the NICE guidance for manufacturers and sponsors and some main issues for its future development are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 1031-1038 |
| Number of pages | 8 |
| Journal | Pharmacoeconomics |
| Volume | 20 |
| Issue number | 15 |
| Publication status | Published - 2002 |
Keywords
- ECONOMIC-EVALUATION
- GUIDELINES